Europe Asthma Drugs Market to 2028 - By Size, Share, Growth by End User and Forecast

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. Europe Asthma Drugs Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. Europe Asthma Drugs Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1 The Rising Prevalence of Asthma Leads to an Increase in Demand for Asthma Drugs, Favors the Market Growth

5.2 Market Opportunities

5.2.1 Commercialization of Biologics Creates Significant Opportunities in the Market

5.3 Future Trends

5.3.1 Research Activities and Product Innovations

5.4 Impact of Drivers and Restraints

6. Europe Asthma Drugs Market Regional Analysis

6.1 Europe Asthma Drugs Market Overview

6.2 Europe Asthma Drugs Market Revenue 2019-2028 (US$ Million)

6.3 Europe Asthma Drugs Market Forecast Analysis

7. Europe Asthma Drugs Market Analysis – by Medication

7.1 Quick Relief Medications

7.1.1 Overview
7.1.2 Quick Relief Medications: Europe Asthma Drugs Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Long-Term Control Medications

7.2.1 Overview
7.2.2 Long-Term Control Medications: Europe Asthma Drugs Market – Revenue and Forecast to 2031 (US$ Million)

8. Europe Asthma Drugs Market Analysis – by Route of Administration

8.1 Inhaled

8.1.1 Overview
8.1.2 Inhaled: Europe Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)

8.2 Prefilled Syringe/Vials

8.2.1 Overview
8.2.2 Prefilled Syringe/Vials: Europe Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)

9. Europe Asthma Drugs Market Analysis – by Distribution Channel

9.1 Online Pharmacies

9.1.1 Overview
9.1.2 Prefilled Syringe/Vials: Europe Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)

9.2 Hospital Pharmacies

9.2.1 Overview
9.2.2 Prefilled Syringe/Vials: Europe Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)

9.3 Retail Pharmacies

9.3.1 Overview
9.3.2 Prefilled Syringe/Vials: Europe Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)

10. Europe Asthma Drugs Market – Europe Analysis

10.1 Europe

10.1.1 Europe Asthma Drugs Market Breakdown, by Key Country, 2022 and 2028 (%)
10.1.1.1 Europe Asthma Drugs Market – Revenue and Forecast Analysis – by Country
10.1.1.1 UK: Europe Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.1.1 UK: Europe Asthma Drugs Market Breakdown, by Medication
10.1.1.1.2 UK: Europe Asthma Drugs Market Breakdown, by Route of Administration
10.1.1.1.3 UK: Europe Asthma Drugs Market Breakdown, by Distribution Channel

10.1.1.2 Germany: Europe Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.2.1 Germany: Europe Asthma Drugs Market Breakdown, by Medication
10.1.1.2.2 Germany: Europe Asthma Drugs Market Breakdown, by Route of Administration
10.1.1.2.3 Germany: Europe Asthma Drugs Market Breakdown, by Distribution Channel

10.1.1.3 France: Europe Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.3.1 France: Europe Asthma Drugs Market Breakdown, by Medication
10.1.1.3.2 France: Europe Asthma Drugs Market Breakdown, by Route of Administration
10.1.1.3.3 France: Europe Asthma Drugs Market Breakdown, by Distribution Channel

10.1.1.4 Russia: Europe Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.4.1 Russia: Europe Asthma Drugs Market Breakdown, by Medication
10.1.1.4.2 Russia: Europe Asthma Drugs Market Breakdown, by Route of Administration
10.1.1.4.3 Russia: Europe Asthma Drugs Market Breakdown, by Distribution Channel

10.1.1.5 Italy: Europe Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.5.1 Italy: Europe Asthma Drugs Market Breakdown, by Medication
10.1.1.5.2 Italy: Europe Asthma Drugs Market Breakdown, by Route of Administration
10.1.1.5.3 Italy: Europe Asthma Drugs Market Breakdown, by Distribution Channel

10.1.1.6 Rest of Europe: Europe Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.6.1 Rest of Europe: Europe Asthma Drugs Market Breakdown, by Medication
10.1.1.6.2 Rest of Europe: Europe Asthma Drugs Market Breakdown, by Route of Administration
10.1.1.6.3 Rest of Europe: Europe Asthma Drugs Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Europe Asthma Drugs Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 AstraZeneca

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 TEVA PHARMACEUTICAL INDUSTRIES LTD

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 GlaxoSmithKline plc.

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Boehringer Ingelheim International GmbH

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 GlaxoSmithKline plc.

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Merck & Co., Inc.

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Koninklijke Philips N.V.

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Sanofi

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 Pfizer Inc. (Arena Pharmaceutical GmbH)

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Novartis AG

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

13.11 Abbott

13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments

14. Appendix

14.1 About Business Market Insights